Longitudinal Tracing of Spontaneous Regression and Anti-angiogenic Response of Individual Microadenomas during Colon Tumorigenesis

Angiogenesis is essential for the progression of cancer, but its involvement in the initial phase of colon tumorigenesis is not well understood. Using intravital endomicroscopy, we visualized the natural history of early pre-tumorous lesions and adenomas in the colon of conditional Apc-knockout and Apc/Kras double mutant mouse models. Early lesions emerged about 4 weeks after the onset of somatic mutations, accompanying vascular dilation when the size of lesions reached about 200 μm, but most lesions regressed spontaneously and cleared within 10 weeks after their emergence. Anti-angiogenic treatments with vascular endothelial growth factor receptor (VEGFR) antagonists reduced the size of the early lesions and the number of polyps. We found surprisingly that anti-angiogenic treatments delayed the natural clearance of transient lesions by up to several weeks in both genetic models. The results represent the previously unexpected role of early angiogenesis on the spontaneous regression of early-stage colon tumors.

[1]  S. Yun,et al.  In vivo imaging of Lgr5-positive cell populations using confocal laser endomicroscopy during early colon tumorigenesis , 2014, Endoscopy.

[2]  Pilhan Kim,et al.  Fabrication and operation of GRIN probes for in vivo fluorescence cellular imaging of internal organs in small animals , 2012, Nature Protocols.

[3]  Holger Gerhardt,et al.  Basic and Therapeutic Aspects of Angiogenesis , 2011, Cell.

[4]  Vadim Backman,et al.  Neo-angiogenesis and the premalignant micro-circulatory augmentation of early colon carcinogenesis. , 2011, Cancer letters.

[5]  P. Carmeliet,et al.  Molecular mechanisms and clinical applications of angiogenesis , 2011, Nature.

[6]  B. Molnár,et al.  The Role of the Bone Marrow Derived Mesenchymal Stem Cells in Colonic Epithelial Regeneration , 2011, Pathology & Oncology Research.

[7]  E. Tartour,et al.  A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients , 2010, Journal of immunotherapy.

[8]  Euiheon Chung,et al.  In vivo wide-area cellular imaging by side-view endomicroscopy , 2010, Nature Methods.

[9]  Umar Mahmood,et al.  Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment , 2010, Proceedings of the National Academy of Sciences.

[10]  J. Zimmer,et al.  Cytokine Levels Correlate with Immune Cell Infiltration after Anti-VEGF Therapy in Preclinical Mouse Models of Breast Cancer , 2009, PloS one.

[11]  M. Mohammadi,et al.  The FGF family: biology, pathophysiology and therapy , 2009, Nature Reviews Drug Discovery.

[12]  Erik Sahai,et al.  Illuminating the metastatic process , 2007, Nature Reviews Cancer.

[13]  Young L. Kim,et al.  Inducible nitric oxide synthase (iNOS) mediates the early increase of blood supply (EIBS) in colon carcinogenesis , 2007, FEBS letters.

[14]  F. Peale,et al.  Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice , 2007, Proceedings of the National Academy of Sciences.

[15]  M. Neurath,et al.  High resolution colonoscopy in live mice , 2006, Nature Protocols.

[16]  Miguel Abal,et al.  APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. , 2006, Gastroenterology.

[17]  R. Poulsom,et al.  Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer. , 2006, Carcinogenesis.

[18]  S. Kyo,et al.  In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus , 2006, Nature Medicine.

[19]  Andrea Sbarbati,et al.  Early Antiangiogenic Activity of SU11248 Evaluated In vivo by Dynamic Contrast-Enhanced Magnetic Resonance Imaging in an Experimental Model of Colon Carcinoma , 2005, Clinical Cancer Research.

[20]  Il-Jin Kim,et al.  [Hereditary colorectal cancer]. , 2005, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.

[21]  M. Nowak,et al.  Linear Model of Colon Cancer Initiation , 2004, Cell cycle.

[22]  J. Segall,et al.  Intravital imaging of cell movement in tumours , 2003, Nature Reviews Cancer.

[23]  J. Bernheim,et al.  Angiogenic switch in earliest stages of human colonic tumorigenesis. , 2003, Anticancer research.

[24]  L. Ellis,et al.  Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors , 2001, British Journal of Cancer.

[25]  L. Ellis,et al.  Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis. , 2001, International journal of oncology.

[26]  Junji Kato,et al.  Aberrant crypt foci of the colon as precursors of adenoma and cancer , 1998, The New England journal of medicine.

[27]  J. Bernheim,et al.  Aberrant crypt foci in human colons: distribution and histomorphologic characteristics. , 1998, Human pathology.

[28]  K. Kinzler,et al.  Lessons from Hereditary Colorectal Cancer , 1996, Cell.

[29]  J. Heath,et al.  EPITHELIAL CELL MIGRATION IN THE INTESTINE , 1996, Cell biology international.

[30]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[31]  C. Heldin,et al.  PDGF receptors as targets in tumor treatment. , 2007, Advances in cancer research.